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Abstract
BCL2 associated Athano-Gene 1 (BAG1) is a multifunctional protein that has been described to be involved in different cell
processes linked to cell survival. It has been reported as deregulated in diverse cancer types. Here, BAG1 protein was found
highly expressed in children with acute myeloid leukemia at diagnosis, and in a cohort of leukemic cell lines. A silencing
approach was used for determining BAG1’s role in AML, finding that its down-regulation decreased expression of BCL2, BCL-
XL, MCL1, and phospho-ERK1/2, all proteins able to sustain leukemia, without affecting the pro-apoptotic protein BAX.
BAG1 down-regulation was also found to increase expression of BAG3, whose similar activity was able to compensate the
loss of function of BAG1. BAG1/BAG3 co-silencing caused an enhanced cell predisposition to death in cell lines and also in
primary AML cultures, affecting the same proteins. Cell death was CASPASE-3 dependent, was accompanied by PARP
cleavage and documented by an increased release of pro-apoptotic molecules Smac/DIABLO and Cytochrome c. BAG1 was
found to directly maintain BCL2 and to protect MCL1 from proteasomal degradation by controlling USP9X expression,
which appeared to be its novel target. Finally, BAG1 was found able to affect leukemia cell fate by influencing the
expression of anti-apoptotic proteins crucial for AML maintenance.
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Introduction
Childhood Acute Myeloid Leukemia (AML) is a clonal disorder
characterized by an accumulation of malignant hematopoietic
progenitors blocked at various stages of normal myeloid
development. Regular proliferation and survival of hematopoietic
cells is largely regulated by apoptotic processes which, when
severely impaired, could contribute to the pathogenesis of
leukemia [1]. The apoptosis-related B cell lymphoma-2 (BCL2)
protein family, with its pro-apoptotic (BAX, BAK) and anti-
apoptotic (BCL2, MCL1, BCL-XL) members, presents a series of
biochemical and cellular events that might be targeted as novel
molecular therapeutics [2]. In general, when pro-apoptotic
proteins prevail over anti-apoptotic ones, apoptosis occurs [2–4].
In AML patients, increased expression of anti-apoptotic BCL2
family proteins has been associated with resistance to chemother-
apy, decreased rates of complete remission, and abbreviated
survival [5–8].
BCL2 associated AthanoGene-1 (BAG1) is a multifunctional
protein able to delay cell death by a synergistic action with BCL2
[9]. BAG1 has been described as a part of the regulation of
apoptotic, transcriptional, and proliferative pathways, as well as
cell signaling and differentiation, although the precise mechanism
that lies behind these events has yet to emerge [10–12].
Implication of BAG1 in a variety of cellular functions is partially
a result of the different subcellular localization of three major
BAG1 protein isoforms: nuclear BAG1L (50 kDa), nuclear/
cytosolic BAG1M (46 kDa), and cytosolic BAG1 (36 kDa), while
the fourth cytosolic isoform of 29 kDa (BAG1S) is less expressed
[13,14]. All isoforms are generated from a single mRNA transcript
using alternative translation-start sites [15]. As a result, they share
the same C-terminus, but differ in N-terminal extension which,
through the ubiquitin-like (UBL) domain, enables interaction
between BAG1 and proteasome [16]. The involvement of
ubiquitin/proteasome system in the degradation of cellular
proteins that regulate different cellular processes, including
apoptosis, has been studied widely [17,18], and BAG1’s ability
to govern proteasomal degradation of certain proteins, has been
already described [19].
BAG1 shares anti-apoptotic features with another family
member, BAG3. Both, in fact, have been described to interact
with the same partners, such as HSP70 and BCL2, in different
models, playing a role in cell survival and maintenance [11,20–
22]. Moreover, BAG1 and BAG3 have been involved within the
Mitogen-Activated Protein Kinase (MAPK) pathway, principally
through c-RAF activation [21,23], and separate studies confirmed
either BAG1 or BAG3 deregulation in diverse cancer types [24–
28]. In this study, investigation of the potential BAG1 role in AML
development was followed. It’s protein over-expression was found
to maintain the expression of the anti-apoptotic proteins BCL2,
BCL-XL, and MCL1. Moreover, BAG1, either directly or
indirectly, controls proteasome-dependent protein degradation,
extending proliferation and survival of leukemic cells, closely
collaborating with its family member BAG3. In addition, the
identification of USP9X as a novel BAG1 partner contributes to
additional knowledge about AML-evoked processes.
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BAG1 expression in leukemic patients and leukemic cell
lines
We analyzed the expression of three major BAG1 protein
isoforms, BAG1L, -1M, and BAG1, in bone marrow samples from
10 childhood patients with acute leukemia at the moment of
diagnosis and compared it with BAG1 expression in 5 healthy
bone marrow (HBM) specimens. BAG1L and -1M isoforms were
almost undetectable in either total proteins or in proteins from
nuclear fractions of HBM, while BAG1 showed faint expression.
The same expression profile was observed when CD34+ cell
populations isolated from HBM (Figure 1A, Figure S1A). In
examined AML patients, with more than 50% of blasts confirmed
(Figure 1B: pt1=88%; pt2=53%; pt3=95%; pt4=79%), BAG1
protein was found over-expressed. In particular, BAG1 isoform
was always highly expressed, while BAG1L and -1M were
expressed variably in total proteins, but were detectable in nuclear
protein fractions (Figure 1B). Subsequently, the study of BAG1
protein expression in the cohort of AML cell lines (HL60,
NOMO1, NB4, THP1, MV4;11, and ML2) showed BAG1 and -
1M isoforms as the mostly abundant and commonly expressed in
all examined specimens. BAG1L was not detectable in all of the
total protein extracts examined, but, similarly to results obtained
for the patients, was confirmed in nuclear protein fractions
(Figure 1C). BAG1 mRNA expression was screened in AML
patients and cell lines. Results showed large variability demon-
strating no evident linear correlation between mRNA and BAG1
protein expression (calibrated with a pool of HBM samples, Figure
S1B; not significant).
BAG1 silencing affected protein expression in HL60 cell
line
Aberrant BAG1 protein expression in AML suggests it might
play a role in leukemia phenotype maintenance. To address this
issue, BAG1 was silenced in the HL60 cell line. The silencing
resulted in more than 60% of BAG1 reduction 48 h after
transfection at either mRNA or protein level with respect to sc-
siRNA (mean RQBAG1=0.2460.05; n=4; **p,0.01; mean
relative expression of BAG1 protein isoforms=0.4560.05; n=3;
*p,0.05; Figure 2A). Differences in cell vitality (sc-siRNA vs
siBAG1=84.9% vs 79.8%) and apoptotic activation (sc-siRNA vs
siBAG1=10.961.7% vs 14.862.4%; n=3; p.0.05) observed
between sc-siRNA and siBAG1 transfected samples were not
statistically significant (data not shown). Monitoring how protein
levels were influenced by BAG1 silencing, we found a notable
decrease of BCL2 (0.4560.15 fold; n=3; *p,0.05), and also of
BCL-XL (0.860.2 fold), and MCL1 expression (0.660.2 fold;
n=3; p.0.05; Figure 2B). All three proteins were part of the
BCL2 family, and all with anti-apoptotic characteristics. No
significant changes in expression of BAX, an important pro-
apoptotic protein of the BCL2 family, were observed, and same
was for XIAP, protein with anti-apoptotic feature, not belonging
to BCL2 family, while Smac/DIABLO, protein with pro-
apoptotic attribute, increased slightly (1.2060.25 fold; n=3;
p.0.05; Figure 2B). BAG1 reduction also influenced the MAPK
pathway, causing the decrease of the phosphorylated form of the
ERK1/2 protein (0.460.2; n=3; *p,0.05) without changing the
expression of total ERK (Figure 2C). Measuring the BAX/BCL2
protein index, we found a tendency toward increased expression in
siBAG1-silenced samples (BAX/BCL2: sc-siRNA=1.060.2; si-
BAG1=1.660.2; n=3; p.0.05), creating the conditions for
apoptosis triggering by reducing the apoptotic threshold. At the
mRNA level, BAG1 silencing did not produce substantial changes
for either BCL2, MCL1,o rBAX (data not shown), whereas BAG3
mRNA expression was found to increase over time (siBAG1
(24 h, 48 h, 72 h): mean RQBAG1=(0.29, 0.32, 0.45); mean
RQBAG3=(1.25, 2.08, 2.60); n=3; *p,0.05; Figure 3A). We
confirmed an inverse expression between the two genes, by
checking if BAG3 silencing could affect BAG1 expression. We
confirmed the BAG1 mRNA and protein increased levels after
BAG3 silencing (siBAG3 (24 h, 48 h, 72 h): RQBAG3=(0.65, 0.76,
1.10); RQBAG1=(0.85, 1.50, 2.51); n=3; *p,0.05; Figure 3A,B),
as previously seen in another human system by Gamerdinger et al
[29]. These results suggest that leukemic cells used BAG3 to
compensate the enforced reduction of BAG1, in order to maintain
tumor survival.
BAG1/BAG3 co-silencing significantly harmed HL60 cell
line survival
The co-silencing of BAG1 and BAG3 genes (referred further as
BCS) was performed. We confirmed the reduction of their
expression at the RNA and protein levels (Figure 4A). After
BCS, cell vitality was reduced significantly with respect to sc-
siRNA transfected cells (cell vitality (24 h, 48 h, 72 h): mean
values for sc-siRNA=(81.4%, 84.3%, 85.0%) and mean values for
BCS=(73.7%, 76.5%, 75.8%), respectively; n=3; *p,0.05;
**p,0.01). Moreover, apoptosis induction was also confirmed
after 48 h of transfection (Ann+/PI+: sc-siRNA vs BCS=
4.661.2% vs 21.161.3%; n=3; *p,0.05; Figure 4B). Protein
levels were evaluated by immunoblots after 48 h of silencing
because after 72 h of BAG1 silencing, we demonstrated the
upregulation of BAG3 that was known to rescue the BAG1
deficiency (Figure 3): as shown in Figure 4C an evident decrease of
BCL2 protein expression was verified (0.460.1 fold), and of
MCL1 (0.560.1 fold; n=3; *p,0.05), and a lower decrease of
BCL-XL (0.860.2 fold; n=3; p.0.05), while the expression of the
pro-apoptotic molecule BAX was not dramatically changed. The
cleavage of the apoptotic hallmark proteins, CASPASE-3 and
PARP, was found, and an enhanced expression of Smac/
DIABLO was also observed. Phospho-ERK1/2 was found
decreased (relative protein expression: sc-siRNA vs BCS=
1.960.4 vs 1.060.1; n=4; *p,0.05) while total protein was
equally expressed (Figure 4D). The same results in protein
impairment were evident after co-silencing of BAG1 and BAG3
in primary AML cultures (Figure 5A, B and C). Cell death with
mitochondrial involvement is demonstrated here by a documented
Cyt c release (Figure 5B). The analysis of eventual changes in
mRNA expression of the same genes of impaired proteins was also
performed, but results were not informative (data not shown).
BAG1 and BAG3 co-silencing influenced proteasome-
dependent degradation
Since BAG1 interaction with proteasome has been well
documented [16], we wished to understand if this pathway is
connected to the lowered protein expression described. We
blocked proteasome reversibly with the chemical agent Z-LLF
and MG132 after BCS to investigate if the BCS enforced
proteasome dependent protein degradation. We found similar
reproducible results for BAG1 and BAG3, neither of which were
significantly influenced by the block of proteasome activity. The
sc-siRNA mimics the physiological condition where anti-apoptotic
proteins were maintained into leukemic cells to sustain tumor
growth. The block of the proteasome increased their expression
because a quota of those proteins are continuously degraded by
this pathway (2 fold increase protein expression after treatment
confirmed by densitometry). After BCS, BCL2, BCL-XL, and
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recovered after treatment, suggesting that BAG1 plays a crucial
role in preserving these proteins away from degradation. In fact,
when proteasome activity was blocked proteins were found into
cytosol at the same strength of the sc-siRNA (more evident at
20 mM drug concentration) confirming that the BAG1 expression
maintains them away from the proteasome, particularly for MCL1
(by densitometric data: 3 fold recovery increase for BCL-2 for
BCS, 6 fold increase for MCL-1, 2-fold for BCL-XL, Figure 6A),
suggesting that its over-expression in AML is consistent with a low
degradation rate of those proteins. Consistent with a role in
mediating the accumulation of the anti-apoptotic proteins in
cytosol, we co-immunoprecipitate (co-IP) BAG1 and confirmed a
direct interaction between it and the main functional apoptotic
target identified here, BCL2. On the contrary, neither BCL-XL
nor MCL1 were direct BAG1 partners (Figure 6B).
USP9X, a novel interaction partner of BAG1
Since MCL1 protein was mainly affected by BAG1 silencing, we
looked for other regulatory proteins through which BAG1 could
affect its expression. After excluding Aurora-A (data not shown)
[30], we found that both, BAG1 and MCL1, immunoprecipitated
with USP9X (Figure 7A). This deubiquitinase was shown to
control the ubiquitination status of MCL1 protein in AML cells,
and here we discovered that USP9X is directly controlled by
BAG1. The expression of the USP9X was confirmed to be
decreased after BCS (Figure 7B). Hence, the impaired expression
of USP9X through BAG1 silencing might affect its interaction
with MCL1, creating a conditions for more intensive MCL1
ubiquitination, we immunoblotted MCL1 after silencing BAG1
and found that MCL1 reduced its expression, and moreover
increased its ubiquitination (Figure 7C), confirming that BAG1
silencing controls MCL1 expression through USP9X.
Discussion
It is generally accepted that carcinogenesis is a complicated
process that involves many steps for transformation of cells to
occur. In childhood Acute Myeloid Leukemia (AML), recent
improvements in the outcome have often been related to the
Figure 1. BAG1 protein expression in a cohort of leukemia patients and leukemic cell lines. A) Western Blot (WB) analysis for the study of
the expression of three major BAG1 protein isoforms in total protein extracts, and expression of BAG1in CD34+ and CD34- cell fractions sorted from
HBM. HL60 cell line is used as positive control B) WB analysis of the expression of BAG1 isoforms in total protein extracts and BAG1L/-1M expression in
nuclear proteins isolated from four AML samples at diagnosis (Diag) and from human AML cell lines (C). b-ACTIN is shown as total and HDAC1 as
nuclear proteins loading control.
doi:10.1371/journal.pone.0026097.g001
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survival rate is continuously improving, a critical number of
patients encounter relapse because they are resistant to current
therapies [33]. Therefore, there is a need to understand the
molecular pathogenesis of hematopoietic cancers better and to
identify new potential molecular targets for treatment.
Altered apoptosis is an important phenomenon responsible for
tumorigenesis. BAG1 is a newly discovered anti-apoptotic protein
that has been proven to be a multifunctional binding molecule that
can enhance the ability of cells to overcome BCL2-mediated
protection from apoptosis [34]. The essential role of BAG1 for the
survival and differentiation of hematopoietic and neuronal cells
has been confirmed by BAG1 knock-out experiments in mice [35].
However, little is known about BAG1 expression and the
mechanism of action in leukemic cells of myeloid origin, where
other apoptosis-related BCL2 family proteins have been described
to be possible molecular therapeutic targets [36].
The first evidence that BAG1 protein is over-expressed in a
group of AML patients and leukemic cell lines with respect to
healthy donors implied that BAG1 might contribute to leukemia
pathogenesis. Additionally, an observed nonlinear correlation
between mRNA and BAG1 protein isoform expression levels
indicated that a post-transcriptional finely-controlled mechanism
might play a crucial role in dictating the final expression of each
BAG1 protein isoform in AML.
BAG1 has recently been found implicated in the field of
leukemia. It was shown to direct CHIP/Hsc70-regulated protein
triage decisions on BCR-ABL immediately after translation to the
degradation pathway [37]. Silencing of BAG1 in our AML model
was shown to considerably reduce the expression of BCL2, a
protein known to be an essential anti-apoptotic effector with
important implications in drug resistance, but also of MCL1 and
BCL-XL, whose involvement in AML has been well documented
[38–40]. The observed impairment of the three key anti-apoptotic
molecules conferred to BAG1 a crucial role in the control of
apoptosis in AML. BAG1 silencing affected significantly the
MAPK-pathway, specifically through down-regulation of ERK1/2
activity, upholding this proliferative pathway to be in part
maintained by BAG1, as described in other cell types [41].
Despite these findings, only a slight decrease in cell vitality and
insignificant apoptosis activation was observed, indicating that
leukemic cells were able to successfully over-come the transient
reduction of BAG1 expression. The observation that BAG3 mRNA
and protein levels were up-regulated after BAG1 silencing
revealed that BAG3, structurally and functionally similar to
BAG1, was induced to compensate for BAG1 deprivation, and to
maintain a sort of survival rescue of the leukemic cells. A similar
functional compensation was previously reported for these two
BAG members in other systems [29]. A significant impact on cell
behavior was then induced by co-silencing both, BAG1 and BAG3,
genes. Co-silencing caused death of leukemic cell lines and
primary AML cultures. A down-regulation of BCL2 and phospho-
ERK1/2, and a more significant reduction in MCL1 protein
expression, were found.
Figure 2. BAG1 silencing in the HL60 cell line. A) BAG1 mRNA and protein expression after silencing are shown. Histogram shows the relative
quantification (RQ) of BAG1 mRNA expression compared to control sc-siRNA silenced HL60 cells (RQ=1 in the figure; n=4; **p,0.01). WB analysis
confirmed that all three BAG1 protein isoforms were down-regulated after transfection with BAG1 specific siRNA. B) Analysis of pro- and anti-
apoptotic proteins expression 48 h post-transfection. C) Expression of MAPK pathway-related proteins validated by WB, 48 h after siBAG1 or sc-siRNA
transfection. b-ACTIN is shown as total protein loading control.
doi:10.1371/journal.pone.0026097.g002
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protein expression impairment that triggered apoptosis in AML.
Among two BAG members considered here, BAG1 is preferen-
tially connected with proteasomal machinery, while BAG3 is
described to be involved with autophagy [16,29]. Therefore, we
considered the impact of proteasome inhibition on protein
expression after BAG1 and BAG3 co-silencing. A rescue from
proteasome degradation of the anti-apoptotic proteins was found,
confirming that degradation of BCL2, BCL-XL, and MCL1
occurred preferentially in a proteasome-dependent way after
down-regulation of BAG proteins [42,43]. As we confirmed, BCL2
protection can be influenced through a direct interaction with
BAG1 protein. Interestingly, we identified the deubiquitinase
USP9X responsible for an indirect down-regulation of the pro-
survival protein MCL1 and consequently, apoptosis triggering.
The USP9X deubiquitinase has recently been reported to regulate
the stability of MCL1 [44], an anti-apoptotic protein expressed in
many tumors and associated with drug resistance and survival
[40]. The reduced USP9X and MCL1 levels were recently found
to block BCR-ABL kinase signaling, taking chronic myelogenous
leukemia cells to apoptosis [45]. Here, we identified BAG1 as the
real culprit of that apoptotic phenomenon, implying a more
important role of BAG1 in AML than previously thought.
Most tumor cells are ‘‘primed’’ for apoptosis, containing a
sufficient quantity of pro-apoptotic molecules to effectively trigger
cell death, but remain protected by highly expressed anti-apoptotic
proteins. Apoptosis-related processes have been reported to be
significant in AML, connecting the BAX/BCL2 ratio with the
clinical outcome of patients with de novo AML, and elevated
MCL1 expression with AML relapses [8,46,47]. Here, we propose
that targeting BAG1 or BAG3 or other specific ubiquitin-
regulators, such as USP9X, may emerge as a novel therapeutic
approach to inhibit AML by reducing elevated apoptotic
threshold.
In conclusion, we describe a supporting role of BAG1 in the
proliferation capacities of myeloid cells, where it maintains a close
relationship with BAG3. The down-regulation of both genes
restricts cell survival by potentiating proteasome-derived degra-
dation of main pro-survival BCL2 family members, directly or
indirectly. USP9X, the important regulator of MCL1 expression
[44], has emerged as an interacting partner of BAG1. Considering
all results, it is likely that BAG1 does not have a direct anti-
apoptotic role in AML cells, but rather performs this function by
supporting the expression of other pro-survival molecules.
However, further studies need to be done to complete a full
image of the working mechanism of BAG1 in AML. Investigations
of both BAG members included here may help in better defining a
potentially effective therapeutic strategy involving silencing of
BAGs or antibody-mediated targeting of BAGs, likely favoring the
development of more potent cancer therapy.
Materials and Methods
Cell lines, primary cell cultures and patient samples
Human AML cell line HL60 (American Type Culture
Collection) was cultured in Dulbecco’s modified Eagle medium
(DMEM; Invitrogen; Carlsbad, CA), supplemented with 10% fetal
bovine serum (FBS; Invitrogen), 1 mg/mL of glutamine, and 1 mg/
mL of penicillin/streptomycin (GIBCOH - Invitrogen). Human
myeloid cell lines NOMO1, NB4, THP1, MV4;11, and ML2 (all
from the American Type Culture Collection) were cultured in
RPMI 1640 (Invitrogen) supplemented with 10% FBS, 1 mg/mL
of glutamine, and 1 mg/mL of penicillin/streptomycin (GIBCOH -
Invitrogen). Analysis of the BAG1 RNA expression in bone
marrow samples of 10 newly diagnosed cases of pediatric AML
was performed, as well as a series of 10 healthy controls (HBM).
Diagnosis of leukemia was carried out according to standard
morphologic criteria based on immunohistochemical, immuno-
Figure 3. BAG1 and BAG3 mRNA and protein expression in HL60 cells. A) HL60 cells were subjected to silencing of BAG1 (siBAG1) and BAG3
(siBAG3) and subsequently checked for relative mRNA expression. RQ-values at 24 h, 48 h, and 72 h of transfection are shown after being normalized
to GUS gene and calibrated to sc-siRNA values. The RQ values are presented on a logarithmic scale. B) WB analysis of BAG1 and BAG3 expression after
silencing is presented, as well as the reciprocal protein increase induced after single silencing. b-ACTIN was a control for an equivalent sample
loading.
doi:10.1371/journal.pone.0026097.g003
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AML treatment protocols [48]. In compliance with the Helsinki
protocol, informed consent was obtained from parents. Primary
cultures of bone marrow from newly diagnosed AML patients
were also studied. Cells were maintained in serum-free RPMI
medium (Invitrogen) with 1 mg/mL of glutamine and 1 mg/mL of
penicillin/streptomycin (GIBCOH - Invitrogen), interleukin-3 (IL-
3) and interleukin-6 (IL-6) (20 ng/mL each; Inalco; Milano, Italy),
stem cell factor (SCF), FMS-like tyrosine kinase 3 (Flt-3) ligand,
and thrombopoietin (TPO) (50 ng/mL each; Inalco) for 24 h and
subsequently subjected to transfection as indicated in the
Transient transfection assay section.
RNA isolation and Reverse transcriptase polymerase
chain reaction (RT-PCR)
Total cellular RNA from cell lines and patient bone marrow was
extracted with TRIzol reagent (Invitrogen). RNA quality was
controlled using an Agilent 2100 Bioanalyzer (Agilent Technolo-
gies; Tokyo, Japan). Subsequently, 1 mg of total RNA was
reversely transcribed using random hexamers and Superscript II
(Invitrogen), according to the manufacturer’s instructions. The
synthesized cDNA was used for PCR analysis. Primers were
generated using Primer Express1.0 software (Table S1), and PCR
products sequenced for adequate gene origin confirmation (data
not shown).
Real-time quantitative RT-PCR (RQ-PCR)
RQ-PCR was performed on an Applied Biosystems 7900 HT
Sequence Detection System using SYBR Green PCR Master
Mixture Reagents (Applied Biosystems; Forest City, CA). Exper-
iments were performed minimum as triplicate and used for relative
quantity study. Primers used for RQ-PCR analysis are listed in
Table S1. All expression values were normalized using expression
of GUS as an endogenous control [49]. For a certain genes (BCL2;
Figure 4. BAG1/3 co-silencing (BCS) in HL60 cells. A) WB after co-silencing is shown at 48 h after transfection. B) Cell vitality was calculated by
trypan-blue exclusion assay after BAG1/3 co-silencing (BCS). The first graph shows the percent of living cells 24 h, 48 h, and 72 h after BCS (white
bars), or silencing with control sc-siRNA (black bars); the second graph shows the percent of apoptotic (Ann+/PI+) cells 48 h after transfection. Data
are presented as mean 6 S.E.M. of three independent measurements (n=3; *p,0.05, **p,0.01). C) The expression of pro- and anti-apoptotic
proteins was validated by WB 48 h post-transfection. Additionally, expression of apoptotic hallmarks, CASPASE-3 and PARP, and their cleavage (cl)
was examined. D) WB analysis for the expression of MAPK pathway-related protein ERK1/2 after transfection with siBAG1/3 or sc-siRNA. b-ACTIN, and
c-TUBULIN are shown as total protein loading controls.
doi:10.1371/journal.pone.0026097.g004
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low density immune array profile (Applied Biosystems), and results
were interpreted by the comparative DDCt method [50].
Transient transfection assay
Transfection experiments were performed on HL60 and
primary cell cultures. For a single BAG1 silencing, increasing
amounts (0.05–0.4 nmol) of specific exogenous small interfering
RNAs (siRNA; Santa Cruz (SC) Biotechnology, Santa Cruz, CA)
were initially tested, confirming a ratio between 0.15–0.2 nmol as
optimal for adequate silencing result. In co-silencing experiments,
cells were transfected with specifically recognizing BAG1
(0.15 nmol) and BAG3 (0.2 nmol) siRNA (SC Biotechnology)
using Q-017 (HL60) or U-015 (primary cultures) programs from
Amaxa Nucleofactor system (Lonza; Cologne, Germany). Applied
amounts of siRNA were chosen as optimal for co-silencing, after
testing diverse combination, giving acceptable down-regulation
efficiency of approximately 70% and avoiding toxic effects on the
cells. In both cases, corresponding amount of non-silencing
scramble siRNA (sc-siRNA; SC Biotechnology) was used as a
control. After transfection, cells were maintained in DMEM
(HL60) or RPMI, supplemented with growth factors (primary
AML cultures) as described above and with 10% of FBS.
Apoptosis assay
Cell death was quantified using fluorescein labeled Annexin-V/
Propidium Iodide (Ann/PI; Immunostep S.L; Salamanca, Spain).
The experimental results were analyzed by a Cytomics FC500
(Beckman Coulter; Brea, CA) for a minimum of 10,000 events.
Preparation of total protein extracts and nuclear protein
fraction
Cells were collected and resuspended in lysis buffer (Biosource
International; Camarillo, CA), supplemented with 0.5 mM
PhenylMethaneSulfonyl Fluoride (PMSF, Sigma-Aldrich), mam-
malian protease, and phosphatase inhibitor mixture (both 16,
Sigma-Aldrich), for 30 min on ice for total protein isolation. For
the cytosol and nuclear protein isolation, a combination of low salt
buffer A (10 mM HEPES pH=7.9; 1.5 mM MgCl2; 10 mM
KCL; and 0.5 mM DTT) and high salt buffer C (20 mM HEPES
pH=7.9; 25% v/v glycerol; 0.42 M NaCl; 1.5 mM MgCl2;
0.2 mM EDTA; and 0.5 mM DTT) was used. Briefly, cell pellets
were resuspended in cold buffer A, kept 10 min on ice, and
centrifuged at 13,000 rpm for 10 min at 4uC. Supernatants with
the cytosol protein fractions were separated, and pellets were
gently washed once with cold 16 PBS and re-resuspended in
buffer C. Thirty minutes later, the nuclear protein fraction was
collected by centrifugation at 13,000 rpm for 30 min at 4uC. Total
proteins or proteins from cytosol or nuclear fractions were
immediately quantified with a BCA Protein Assay Kit (Pierce;
Rockford, IL).
Western blotting
Aliquots of total or nuclear lysates were subjected to sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE).
Immunoblots were hybridized with the following primary
antibodies: BAG1 (recognizing all three BAG1 isoforms), BAG3,
Ub (SC Biotechnology), total and Phospho-ERK1/2, CASPASE-
3, PARP, BCL2, MCL1, BCL-XL, BAX, Smac/DIABLO,
Cytochrome c (Cyt c), XIAP, Aurora A (Cell Signaling; Danvers,
MA), and USP9X (gift of prof. Piccolo S. and commercial from
Bethyl Laboratories, Montgomery, TX) in concentrations recom-
mended by the manufacturers. Blots were then stripped and re-
probed with b-ACTIN, c-TUBULIN (Sigma-Aldrich) or HDAC1
(SC Biotechnology) antibodies, used as protein loading controls. As
secondary antibodies, horseradish peroxidase (HRP)–conjugated
anti-rabbit, anti-mouse, or anti-goat IgG (Upstate Biotechnology;
Lake Placid, NY) were used. Enhanced chemiluminescence (ECL)
Western blotting detection reagents and films (GE Healthcare;
Figure 5. BAG1/3 co-silencing (BCS) in primary AML cultures. A) WB of co-silencing is shown for BAG1 and BAG3 expression after 48 h of
transfection B) The expression of pro- and anti-apoptotic proteins was validated by WB 48 h post-transfection. Apoptotic hallmarks, CASPASE-3 and
PARP, and their cleavage (cl) was examined. The release of Cyt c was evaluated in cytosol protein fraction. C) WB analysis for ERK1/2 expression after
transfection with siBAG1/3 or sc-siRNA b-ACTIN, and c-TUBULIN are shown as total protein loading controls.
doi:10.1371/journal.pone.0026097.g005
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densitometry was done using ImageJ 1.37v software (National
Institutes of Health; Bethesda; MD) and expression of b-ACTIN
or c-TUBULIN for data normalization.
Co-Immunoprecipitation
For immunoprecipitation (IP) analysis, HL60 and primary AML
cells were harvested, washed once in cold 16 PBS, and
resuspended in IP buffer (5 mM MgCl2, 137 mM KCl, 1 mM
EDTA, 1 mM EGTA, and 20 mM Tris-HCl, pH=7.5 and 1%
CHAPS) containing PMSF, protease, and phosphatase inhibitors
(16; Sigma-Aldrich). After 30 min of incubation on ice, the lysate
was clarified by centrifugation, and the supernatant with total
protein fraction was pre-cleared with Protein A/G MicroBeads
(Miltenyi Biotec, B. Gladbach, Germany) on ice for another
30 min. The lysate was passed over a m-Column and collected for
immunolabeling with anti-BAG1, anti-Aurora A, anti-MCL1 and
anti-BCL-XL antibodies for 30 min on ice (SC Biotechnology).
For immunolabeling with anti-USP9X, and anti-MCL1 and anti-
Ub after BCS, small modification of protocol was introduced,
considering the incubation with MicroBeads over night with
500 mg of total proteins. Subsequently, lysates retaining magnet-
ically labeled protein were run through the m-Column, and after
four washes, eluted with pre-heated (95uC) 16SDS loading buffer.
The immunoprecipitates were analyzed by SDS-PAGE.
Reagents and treatments
Cell viability was determined by trypan-blue (GIBCOH -
Invitrogen) exclusion assay, counting by phase-contrast microscopy.
Proteasome inhibition was obtained using a selective and reversible
proteasome inhibitors MG132 (20 mM; Sigma-Aldrich) and
(benzyloxycarbonyl)-leu-leu-phenylalaninal (Z-LLF-CHO; 10 mM
and 20 mM; Sigma-Aldrich) 48 h post-transfection for 4 hours.
Statistical analysis
Statistical analysis was performed using Prism 4.02 (Graph Pad
Software; La Jolla; CA). All experiments were performed in
triplicate, and mean values are presented as mean 6 standard
error of mean (S.E.M.) of replicate experiments. Statistical
significance was evaluated by the unpaired Student’s t-test.
Differences were considered significant for p,0.05 and presented
as *p,0.05; **p,0.01, ***p,0.001.
Figure 6. Proteasome inhibition study and co-immunoprecipitation analysis. A) WB analyses after BCS and reversible block of proteasome
for 4 h with chemical agents, MG132 (20 mM) and Z-LLF (10 mM and 20 mM), are presented. The eventual changes in BCL2, BCL-XL, and MCL1 protein
expression were checked. p21 served as a standard control for proteasome blocking [51], and b-ACTIN and c-TUBULIN are shown as total protein
loading controls. B) Analysis of possible co-interaction between BAG1/BCL-XL, BAG1/BCL2 and BAG1/MCL1 proteins done by immunoprecipitation
(IP) and WB is shown.
doi:10.1371/journal.pone.0026097.g006
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Figure S1 BAG-1 protein in HBM and mRNA expression
in a cohort of AML patients and AML cell lines. A)
Expression of BAG1 protein isoforms within nuclear protein
fractions isolated from HBM specimens. HDAC1 is shown as
nuclear proteins loading control. B) The BAG1 mRNA expression
was validated for a cohort of AML patients at diagnosis and for the
AML cell lines. Histograms show the relative quantification (RQ)
of BAG1 mRNA expression compared to control samples of
healthy donors (RQ=1 on the figure; n=4; p.0.05). All results
are normalized for GUS as endogenous control.
(TIF)
Table S1 Table of primers used for PCR or RQ-PCR
analyses.
(DOC)
Acknowledgments
We thank Prof. Stefano Piccolo for providing us FAM (USP9X) antibody.
Author Contributions
Conceived and designed the experiments: SA MP. Performed the
experiments: SA. Analyzed the data: SA MP GB. Wrote the paper: SA
MP GB.
References
1. Testa U, Riccioni R (2007) Deregulation of apoptosis in acute myeloid leukemia.
Haematologica 98: 81–94.
2. Tsujimoto Y (2003) Cell death regulation by the BCL2 protein family in the
mitochondria. J Cell Physiol 195: 158–167.
3. Du C, Fang M, Li Y, Li L, Wang X (2000) Smac, a mitochondrial protein that
promotes cytochrome c-dependent caspase activation by eliminating IAP
inhibition. Cell 102: 33–42.
4. Scorrano L, Korsmeyer SJ (2003) Mechanisms of cytochrome c release by
proapoptotic BCL2 family members. Biochem Biophys Res Commun 304: 437–444.
5. Bradbury DA, Russell NH (1995) Comparative quantitative expression of BCL2
by normal and leukaemic myeloid cells. Br J Haematol 91: 374–379.
6. Campos L, Rouault JP, Sabido O, Oriol P, Vasselon C, et al. (1993) High
expression of BCL2 protein in acute myeloid leukemia cells is associated with
poor response to chemotherapy. Blood 81: 3091–3096.
Figure 7. USP9X protein expression and co-immunoprecipitation analysis. A) Analysis of co-interaction between BAG1/USP9X and USP9X/
MCL1 proteins was shown. IP assay was done with BAG1 and USP9X primary antibodies and IB with anti-BAG1, anti-USP9X or anti-MCL1 primary
antibodies. B) Effects of BCS on USP9X and MCL1 protein expression were analyzed by WB. b-ACTIN is shown as total protein loading control. C) MCL1
was immunoprecipitated after silencing, and the IB analyses with anti-MCL1 and anti-Ubiquitin (Ub) proteins were done. The arrows indicate an
increased smear of ubiquitinated proteins after BCS. Asterisk indicates the cleaved form of Mcl-1 [52].
doi:10.1371/journal.pone.0026097.g007
BAG1 Influences Apoptosis in Myeloid Leukemia
PLoS ONE | www.plosone.org 9 October 2011 | Volume 6 | Issue 10 | e260977. Bensi L, Longo R, Vecchi A, Messora C, Garagnani L, et al. (1995) BCL2
oncoprotein expression in acute myeloid leukemia. Haematologica 80: 98–102.
8. Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, et al. (1998)
Elevated expression of the apoptotic regulator MCL1 at the time of leukemic
relapse. Blood 91: 991–1000.
9. Takayama S, Sato T, Krajewski S, Kochel K, Irie S, et al. (1995) Cloning and
functional analysis of BAG1: a novel BCL2 binding protein with anti-cell death
activity. Cell 80: 279–284.
10. Townsend PA, Cutress RI, Sharp A, Brimmell M, Packham G (2003) BAG1: a
multi functional regulator of cell growth and survival. Biochim Biophys Acta
1603: 83–89.
11. Doong H, Vrailas A, Kohn EC (2002) What’s in the ‘BAG’?—A functional
domain analysis of the BAG-family proteins. Cancer Lett 188: 25–32.
12. Townsend PA, Stephanou A, Packham G, Latchman DS (2005) BAG1: A multi-
functional pro-survival molecule. Int J Biochem Cell Biol 37: 251–259.
13. Takayama S, Krajewski S, Krajewska M, Kitada S, Zapata JM, et al. (1998)
Expression and location of Hsp70/Hsc-Binding anti-apoptotic protein BAG1
and its variants in normal tissues and tumour cell lines. Cancer Res 58:
3116–3131.
14. Packham G, Brimmell M, Cleveland JL (1997) Mammalian cells express two
differently localized BAG1 isoforms generated by alternative translation
initiation. Biochem J 328: 807–813.
15. Yang X, Chernenko G, Hao Y, Ding Z, Pater MM, et al. (1998) Human BAG1/
Rap46 protein is generated as four isoforms by alternative translation initiation
and over-expressed in cancer cells. Oncogene 17: 981–989.
16. Luders J, Demand J, Hohfeld J (2000) The ubiquitin-related BAG1 provides a
link between the molecular chaperones Hsc70/Hsp70 and the proteasome. J Biol
Chem 275: 4613–4617.
17. Hochstrasser M (1995) Ubiquitin, proteasomes and the regulation of
intracellular protein degradation. Curr Opin Cell Biol 7: 215–223.
18. Dou QP, Li B (1999) Proteasome inhibitors as potential novel anticancer agents.
Drug Resist Updates 2: 215–223.
19. Elliott E, Tsvetkov P, Ginzburg I (2007) BAG-1 associates with Hsc70-Tau
complex and regulates proteasomal degradation of Tau protein. J Biol Chem
282: 37276–37284.
20. Takayama S, Xie Z, Reed JC (1999) An evolutionary conserved family of
Hsp70/Hsc70 molecular chaperone regulators. EMBO J 21: 6135–6143.
21. Doong H, Rizzo K, Fang S, Kulpa V, Weissman AM, et al. (2003) CAIR-1/
BAG3 abrogates heat shock protein-70 chaperone complex-mediated protein
degradation: accumulation of poly-ubiquitinated Hsp90 client proteins. J Biol
Chem 278: 28490–28500.
22. Lee JH, Takahashi T, Yasuhara N, Inazawa J, Kamada S, et al. (1999) Bis, a
BCL2-binding protein that synergizes with BCL2 in preventing cell death.
Oncogene 18: 6183–6190.
23. Wang HG, Takayama S, Rapp UR, Reed JC (1996) BCL2 interacting protein,
BAG1, binds to and activates the kinase Raf-1. Proc Natl Acad Sci USA 93:
7063–7068.
24. Brimmell M, Burns JS, Munson P, McDonald L, O’Hare MJ, et al. (1999) High
level expression of differentially localized BAG1 isoforms in some oestrogen
receptor-positive human breast cancers. Br J Cancer 81: 1042–1051.
25. Kudoh M, Knee DA, Takayama S, Reed JC (2002) BAG1 proteins regulate
growth and survival of ZR-75-1 human breast cancer cells. Cancer res 62:
1904–1909.
26. Rosati A, Ammirante M, Gentilella A, Basile A, Festa M, et al. (2007) Apoptosis
inhibition in cancer cells: a novel molecular pathway that involves BAG3
protein. Int J Biochem Cell Biol 39: 1337–1342.
27. Cutress RI, Townsend PA, Brimmell M, Bateman AC, Hague A, et al. (2002)
BAG1 expression and function in human cancer. Br J Cancer 87: 834–839.
28. Bonelli P, Petrella A, Rosati A, Romano MF, Lerose R, et al. (2004) Bag3
protein regulates stress-induced apoptosis in normal and neoplastic leukocytes.
Leukemia 18: 358–360.
29. Gamerdinger M, Hajieva P, Kaya AM, Wolfrum U, Hartl FU, et al. (2009)
Protein quality control during aging involves recruitment of the macroautophagy
pathway by BAG3. EMBO J 28: 889–901.
30. Cammareri P, Scopelliti A, Todaro M, Eterno V, Francescangeli F, et al. (2010)
Aurora-A is Essential for the Tumorigenic Capacity and Chemoresistance of
Colorectal Cancer Stem Cells. Cancer Res 70: 4655–4665.
31. Pession A, Rondelli R, Basso G, Rizzari C, Testi AM, et al. (2005) Treatment
and long-term results in children with acute myeloid leukaemia treated
according to the AIEOP AML protocols. Leukemia 19: 2043–2053.
32. Frascella E, Rondelli R, Pigazzi M, Zampieron C, Fagioli F, et al. (2004) Clinical
features of childhood acute myeloid leukaemia with specific gene rearrange-
ments. Leukemia 18: 1427–1429.
33. Ko RH, Ji LY, Barnette P, Bostrom B, Hutchinson R, et al. (2010) Outcome of
Pediatric Patients Treated for Relapsed or Refractory Acute Lymphoblastic
Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium Study.
JCO 28: 648–654.
34. Cheng J, Xiong J, Liu H, Chernenko G, Tang SC (2002) Distinct BAG1
isoforms have different anti-apoptotic functions in BAG1-transfected C33A
human cervical carcinoma cell line. Oncogene 21: 7050–7059.
35. Gotz R, Wiese S, Takayama S, Camarero GC, Rossoll W, et al. (2005) BAG1 is
essential for differentiation and survival of hematopoietic and neuronal cells. Nat
Neurosci 8: 1169–1178.
36. Konopleva M, Tari AM, Estrov Z, Harris D, Xie Z, et al. (2000) Liposomal
BCL2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid
leukemia to cytosine-arabinoside and induce apoptosis independent of other
anti-apoptotic proteins. Blood 95: 3929–3938.
37. Tsukahara F, Maru Y (2010) Bag1 directly routes immature BCR-ABL for
proteasome degradation. Blood 116: 3582–3592.
38. Maung ZT, MacLean FR, Reid MM, Pearson AD, Proctor SJ, et al. (1994) The
relationship between bcl-2 expression and response to chemotherapy in acute
leukaemia. Br J Haematol 88: 105–109.
39. Konopleva M, Zhao S, Hu W, Jiang S, Snell V, et al. (2002) The anti-apoptotic
genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance
of non-proliferating leukaemic CD34+ cells. Br J Haematol 118: 521–534.
40. Zhou P, Quian L, Kozopas KM, Craig RW (1997) Mcl-1, a Bcl-2 family
member, delays the death of the hematopoietic cells under a variety of apoptosis-
inducing conditions. Blood 89: 630–643.
41. Anderson LR, Sutherland RL, Butt AJ (2010) BAG1 overexpression attenuates
luminal apoptosis in MCF-10A mammary epithelial cells through enhanced
RAF-1 activation. Oncogene 29: 527–538.
42. Michels J, Johnson PW, Packham G (2005) MCL1. Int J Biochem Cell Biol 37:
267–271.
43. Dimmeler S, Breitschopf K, Haendeler J, Zeiher AM (1999) Dephosphorylation
Tragets BCL2 for Ubiquitin-dependent Degradation: A link between the
apoptosome and the proteasome pathway. J Exp Med 189: 1815–1822.
44. Schwickart M, Huang XD, Lill JR, Liu J, Ferrando R, et al. (2010)
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival.
Nature 463: 103–108.
45. Sun H, Kapuria V, Peterson LF, Fang D, Bornmann WG, et al. (2011) Bcr-Abl
ubiquitination and Usp9x inhibition block kinase signaling and promote CML
cell apoptosis. Blood 117: 3151–3162.
46. Del Poeta G, Venditti A, Del Principe MI (2003) Amount of spontaneous
apoptosis detected by BAX/BCL2 ratio predicts outcome in acute myeloid
leukemia (AML). Blood 101: 2125–2131.
47. Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, et al. (2002) Antisense
strategy shows that MCL1 rather than BCL2 or Bcl-XL is an essential survival
protein of human myeloma cells. Blood 100: 194–199.
48. Pession A, Rizzari C, Putti MC, Masetti R, Casale F, et al. (2009) Results of the
AIEOP AML 2002/01 study for treatment of children with acute myeloid
leukemia. Blood 114: 17.
49. Pigazzi M, Manara E, Baron E, Basso G (2009) miR-34b Targets cyclic AMP-
responsive element binding protein in acute myeloid leukemia. Cancer Res 69:
2471–2478.
50. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using
real-time quantitative PCR and the 2
2DDCt method. Methods 25: 402–408.
51. Blagosklonny MV, Wu GS, Omura S, el-Deiry WS (1996) Proteasome-
dependent regulation of p21WAF1/CIP1 expression. Biochem Biophys Res
Commun 227: 564–569.
52. Herrant M, Jacquel A, Marchetti S, Belhacene N, Colosetti P, et al. (2004)
Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced
apoptosis. Oncogene 23: 7863–7873.
BAG1 Influences Apoptosis in Myeloid Leukemia
PLoS ONE | www.plosone.org 10 October 2011 | Volume 6 | Issue 10 | e26097